Delphi Ventures, a trailblazer in life sciences venture capital, boasts over three decades of expertise. Specializing in biopharmaceuticals and medical technology, they've been instrumental in advancing numerous drugs to market approval. Under the leadership of Deepa Pakianathan, PhD, Doug Roeder, and CFO Matthew Potter, Delphi nurtures innovative ideas, focusing on expanding patient access to therapies and enhancing less invasive medical procedures. Their diverse portfolio reflects a commitment to transforming the life sciences landscape.
Delphi Ventures Overview
Delphi Ventures - About
Delphi Ventures is a pioneering venture capital firm with a focus on life sciences, founded over 30 years ago as one of the first to specialize in this sector. They leverage their extensive experience, passion, and expertise to advance new technologies and build market-leading companies. Delphi Ventures has played a significant role in the development of several drugs, leading them to market approval. Their portfolio includes a diverse range of companies, from biopharmaceuticals to medical technology firms, all aimed at expanding therapeutic access for patients and enhancing less invasive medical procedures. The firm's managing partners, Deepa Pakianathan, PhD, and Doug Roeder, along with CFO and Partner Matthew Potter, lead a team dedicated to nurturing groundbreaking ideas in the life sciences arena.
LayerZero